Ireland - English - HPRA (Health Products Regulatory Authority)

cardinal health uk 434 limited - vinorelbine tartrate - concentrate for soln for inf - 10 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vinorelbine tartrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vinorelbine tartrate -

Israel - English - Ministry of Health

novartis israel ltd - vinorelbine as tartrate - concentrate for solution for infusion - vinorelbine as tartrate 10 mg/ml - for the treatment of non small cell lung cancer. for the treatment of advanced breast cancer. hormone- refractory prostate cancer, especially in combination with low dose oral corticoid therapy or estramustin.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml - injection - excipient ingredients: water for injections - vinorelbine tartrate is indicated in the treatment of advanced non-small cell lung cancer (nsclc), as a single agent or in combination. it is also indicated for the treatment of patients with metastatic breast cancer who have failed standard first-line chemotherapy for metastatic disease. in addition vinorelbine tartrate is indicated for the treatment of patients with metastatic breast cancer who have relapsed within 6 months of anthracycline-based adjuvant therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml - injection - excipient ingredients: water for injections - vinorelbine is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced nonsmall cell lung cancer (nsclc). in patients with stage iv nsclc, vinorelbine is indicated as a single agent or in combination with cisplatin. in stage iii nsclc, vinorelbine is indicated in combination with cisplatin.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml - injection - excipient ingredients: water for injections - vinorelbine is indicated in the treatment of: - non-small cell lung cancer (stage 3 or 4) - as a single agent to patients with metastatic breast cancer (stage 4), where treatment with anthracycline- and taxane containing chemotherapy has failed or is not appropriate

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection - excipient ingredients: water for injections - vinorelbine is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced nonsmall cell lung cancer (nsclc). in patients with stage iv nsclc, vinorelbine is indicated as a single agent or in combination with cisplatin. in stage iii nsclc, vinorelbine is indicated with in combination with cisplatin.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml - injection - excipient ingredients: water for injections - vinorelbine tartrate is indicated in the treatment of advanced non-small cell lung cancer (nsclc), as a single agent or in combination. vinorelbine tartrate is also indicated for the treatment of patients with metastatic breast cancer who have failed standard first-line chemotherapy for metastatic disease. in addition, vinorelbine tartrate is indicated for the treatment of patients with metastatic breast cancer who have relapsed within 6 months of anthracycline-based adjuvant therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

new zealand medical & scientific ltd - vinorelbine tartrate 13.85 mg/ml equivalent to 10 mg/ml vinorelbine - solution for injection - 10 mg/ml - active: vinorelbine tartrate 13.85 mg/ml equivalent to 10 mg/ml vinorelbine excipient: water for injection